SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle's stock is under pressure following earnings results that sparked concerns about heavy AI-related spending and its impact on future profitability; the community is closely watching key support levels. Some believe this is an overreaction and a buying opportunity, while others fear the company's debt and cash flow issues could continue to weigh on the stock. Chatter suggests a broader reassessment of AI-exposed companies is underway as investors digest the implications of Oracle's report.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending due to its upcoming Autonomy and AI Day, with community members anticipating announcements around self-driving capabilities and in-house chip technology. Discussions also involve Rivian's potential to compete with Tesla and other EV makers, alongside mentions of production improvements and expansion plans. Overall, the community buzz reflects excitement and high expectations for Rivian's technological advancements in the EV sector.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is trending downwards as investors discuss customer losses and a recent analyst price cut, leading to concerns about its competitive position against larger platforms; the stock is nearing 52-week lows, sparking debates about potential takeover bids and whether it's a buying opportunity or a value trap given tax-loss selling pressures and potential Nasdaq 100 exclusion.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to anticipation surrounding its conference presentation and potential AI/HPC focus, with community members actively discussing a possible short squeeze and high price targets. Speculation about partnership announcements and positive updates are fueling the stock's volatility, while traders closely monitor key resistance levels and dilution concerns. Some traders suggest removing stop losses.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is trending as traders weigh the impact of colder weather forecasts against high natural gas production and storage levels. Community discussions revolve around potential rallies, pullbacks, and the effects of contract rollovers on the ETF. Sentiment appears mixed, with some anticipating further upside and others bracing for a potential downturn.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

GEMI is trending as traders discuss its potential in the prediction markets, fueled by a recent license approval and comparisons to Kalshi's valuation. Community members are pointing to strong buyer interest and potential breakout levels, while some highlight the company's ties to figures like Trump. The conversation also includes discussions around market capitalization and possible short squeezes.

Black Titan Corp. was formed for the purpose of effecting a merger between Titan Pharmaceuticals Inc. and TalenTec Sdn Bhd. It intends to explore and identify viable business opportunities. The company was founded on July 11, 2024 and is headquartered in Petaling Jaya, Malaysia.

Black Titan Corp.

Black Titan Corp. is trending as community members discuss its recent surge following news of its strategic entry into digital assets. Traders are actively debating holding strategies amidst volatility, with some pointing to dilution concerns and potential short squeeze opportunities. The stock's low float and potential for further news related to its digital asset framework are also fueling interest.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices surge, driven by factors such as potential rate cuts and increasing industrial demand. Community members are discussing the possibility of a supply squeeze and potential for further gains, with some highlighting silver's outperformance compared to gold. Some traders are eyeing potential breakouts while remaining cautious of possible pullbacks.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending as investors discuss its potential in treating cancers, particularly after positive data in prostate cancer trials, while also citing undervaluation. The community is actively discussing the possibility of a short squeeze given the high short interest. Some also speculate about potential partnerships and acquisitions in the near future! LOAD!

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending as investors anticipate earnings, especially in light of potential AI chip deals with major tech companies like Microsoft. Community discussions revolve around whether Broadcom can deliver strong guidance and justify its valuation amidst broader concerns of an AI spending slowdown. Bullish sentiment is fueled by expectations of significant AI revenue growth and the company's history of exceeding estimates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates

Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 0.00% and -16.01%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -26.24% and -71.95%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates

Coherus Oncology (CHRS) delivered earnings and revenue surprises of -3.13% and -5.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Exact Sciences (EXAS) Q3 Earnings and Revenues Beat Estimates

Exact Sciences (EXAS) delivered earnings and revenue surprises of +84.62% and +4.97%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains?

Armata Pharmaceuticals (ARMP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

<ul class="summary-bullets"><li>The company’s bacteriophage therapy AP-SA02 achieved an 88% response rate in a Phase 2a trial for Staphylococcus aureus bacteremia, with no relapses reported.</li><li>H.C. Wainwright reiterated a ‘Buy’ rating and $9 target, saying the results support advancing AP-SA02 into Phase 3 next year.</li><li>Retail traders flooded Stocktwits with bullish posts after the record rally, with some predicting further gains while others expected a share offering.</li></ul>Shares of Armata Pharmaceuticals surged to a record high on Wednesday after the company reported encouraging Phase 2a results for its experimental bacteriophage therapy, AP-SA02, in patients with complicated Staphylococcus aureus bacteremia (SAB), a serious and often life-threatening bloodstream infection.The stock logged its best session on record on Wednesday, surging 103% to close at $7.05, and fell 16% in after-hours trading as investors took profits following the steep rally.Promising Results In Early-Stage TrialThe findings show for the first time, in a randomized trial, that intravenous phage therapy can be efficacious for S. aureus bacteremia.&nbsp;The diSArm study showed that patients treated with AP-SA02 in addition to the best available antibiotic therapy had an 88% clinical response rate at day 12, compared with 58% for placebo. No patients treated with AP-SA02 relapsed or were non-responsive, versus approximately 25% of patients who received&nbsp;a placebo.A total of 42 patients were enrolled in the trial, and about 38% of the cases had infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Armata said that the treatment was well-tolerated with no serious adverse events associated with the drug.The company is looking to move AP-SA02 into a Phase 3 trial in 2026, based on these results, subject to regulatory input from the U.S. Food and Drug Administration.Analyst ViewH.C. Wainwright reaffirmed its ‘Buy’ rating and $9 price target on Armata, representing a 28% upside from the company’s last close. The brokerage said the results, along with supporting in vitro data, provide “strong evidence for the efficacy of its core therapeutic strategy.” The firm said the data support moving the bacteriophage therapy into a pivotal late-stage study next year.Multi-Phage Cocktail Shows Broad Efficacy&nbsp;Armata said AP-SA02, a fixed cocktail of multiple bacteriophages, showed consistent efficacy against both MRSA and methicillin-sensitive S. aureus (MSSA) and was linked to faster infection clearance and shorter hospital stays. The company received $26.2 million in funding from the U.S. Department of Defense through the Medical Technology Enterprise Consortium to support the diSArm study.Stocktwits Traders See Potential Stock Offering&nbsp;On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 26,200% surge in 24-hour message volume.One user said they expected the company to announce a share offering following the surge in its stock price.<stembedurl>https://stocktwits.com/FredDurst/message/633328173</stembedurl>Another user, however, struck an optimistic tone, predicting that the stock could double in value the next day.<stembedurl>https://stocktwits.com/Lifeinlight/message/633324622</stembedurl><a href="https://stocktwits.com/symbol/ARMP">Armata’s stock</a> has&nbsp;rocketed 281% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Armata Pharmaceuticals logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Armata Pharmaceuticals Stock Soars To Record High After Phage Therapy Data In Deadly Infection Trial; Retail Traders Pile In

H.C. Wainwright reiterated a ‘Buy’ rating and $9 target, saying the results support advancing AP-SA02 into Phase 3 next year.

Equity

Are Medical Stocks Lagging  Armata Pharmaceuticals (ARMP) This Year?

Here is how Armata Pharmaceuticals, Inc. (ARMP) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year?

Here is how Armata Pharmaceuticals, Inc. (ARMP) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?

Here is how Arbutus Biopharma (ABUS) and Armata Pharmaceuticals, Inc. (ARMP) have performed compared to their sector so far this year.

All You Need to Know About Armata Pharmaceuticals (ARMP) Rating Upgrade to Buy

Armata Pharmaceuticals (ARMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.

Armata Pharmaceuticals Inc

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.19	--	--	N/A
Q3 '25	-$0.42	-$0.74	-76.19%	MISSED
Q2 '25	-$0.39	-$0.45	-15.38%	MISSED
Q1 '25	-$0.38	-$0.20	47.37%	BEAT
Q4 '24	-$0.35	-$0.23	34.29%	BEAT

ARMP
Armata Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest ARMP News

ARMPArmata Pharmaceuticals Inc